MedCity News August 30, 2024
Frank Vinluan

Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic.

As an mpox outbreak in Africa continues to spread, the FDA has approved an Emergent BioSolutions vaccine for preventing infection from this pathogen. The regulatory decision could be the first of several for this vaccine, which is also being discussed with health authorities around the world.

The vaccine, ACAM2000, was initially developed to protect against smallpox. Mpox is a member of the same family of viruses as smallpox. Using a live version of vaccinia, a virus that is related to smallpox but causes milder disease, ACAM2000 is intended to spark the immune system to produce...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID
Related Articles:
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Share This Article